中宠股份(002891) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for the third quarter reached ¥754,729,711.24, representing a year-on-year increase of 19.48%[3] - The net profit attributable to shareholders decreased by 38.11% to ¥31,021,825.64 compared to the same period last year[3] - The net profit after deducting non-recurring gains and losses was ¥31,371,798.67, down 36.32% year-on-year[3] - Total operating revenue for the period reached CNY 2,012,137,366.06, an increase of 24.2% compared to CNY 1,620,139,344.62 in the previous period[20] - Net profit for the period was CNY 105,848,626.40, a decrease of 3.9% from CNY 109,295,473.61 in the previous period[21] - The net profit attributable to the parent company was CNY 91,710,284.40, a decrease from CNY 96,243,402.48 in the previous period, representing a decline of approximately 5.3%[22] - The total comprehensive income attributable to the parent company was CNY 87,327,941.82, down from CNY 89,837,253.18, indicating a decrease of about 2.8%[22] - The basic and diluted earnings per share were both CNY 0.3118, compared to CNY 0.3667 in the previous period, reflecting a decrease of approximately 14.9%[24] Assets and Liabilities - The total assets increased by 21.14% to ¥3,032,013,768.34 compared to the end of the previous year[3] - The company's total assets increased to CNY 3,032,013,768.34, compared to CNY 2,502,840,080.12 in the previous year, reflecting a growth of 21.1%[19] - Current liabilities totaled CNY 925,384,764.48, an increase of 49.3% from CNY 619,356,277.01 in the previous period[18] - Long-term borrowings rose to CNY 89,101,592.37, compared to CNY 25,227,701.87 in the prior year, marking a significant increase of 253.5%[18] - The total liabilities of the company reached CNY 1,101,885,673.28, compared to CNY 666,213,327.45 in the previous year, reflecting a growth of 65.4%[18] - The company's equity attributable to shareholders reached CNY 1,798,112,462.21, up from CNY 1,727,536,522.45, indicating a growth of 4.1%[19] Cash Flow - The company's cash flow from operating activities for the year-to-date period was ¥97,243,408.41, showing a significant increase of 163.14%[3] - Cash inflows from operating activities totaled CNY 1,994,552,777.50, an increase from CNY 1,591,950,975.93, marking a growth of about 25.3%[24] - The net cash flow from operating activities was CNY 97,243,408.41, a significant improvement from a negative CNY 154,020,544.83 in the previous period[26] - Cash inflows from investment activities amounted to CNY 895,604,086.77, compared to CNY 75,780,876.79, showing a substantial increase[26] - The net cash flow from investment activities was negative CNY 242,066,290.68, worsening from negative CNY 168,779,672.50 in the previous period[26] - The net cash flow from financing activities was CNY 268,495,561.34, down from CNY 901,358,827.73, indicating a decrease of approximately 70.3%[27] - The ending balance of cash and cash equivalents was CNY 401,057,700.44, a decrease from CNY 737,297,621.03 in the previous period[27] Investment and R&D - Research and development expenses rose by 33.18% to ¥2,990.38 million, reflecting the company's commitment to increasing R&D investment[8] - Research and development expenses for the period were CNY 29,903,811.96, an increase of 33.4% from CNY 22,454,097.34 in the previous period[21] - The company has initiated new acquisition projects, contributing to the increase in cash outflows for investment activities[9] - The company plans to continue expanding its financial management operations and exploring new investment opportunities[9] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 32,559, with the largest shareholder holding 26.41% of the shares[10] - The largest shareholder, Yantai Zhongxing Biotechnology Co., Ltd., holds 77,685,750 shares, representing 26.41% of the total[10] Inventory and Management - Inventory decreased to CNY 496.96 million from CNY 549.95 million, indicating improved inventory management[15] - The company reported a long-term equity investment of CNY 98,753,938.34, reflecting its strategic investment approach[30]